Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGA003
- Development stage
- Preclinical
- Lead developer
- Biogenera
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
BGA003 is a peptide nucleic acid (PNA) anti-gene oligonucleotide developed by Biogenera for the treatment of various cancers. It utilizes Biogenera's proprietary Ag-PNA technology platform to target the *MYC* gene. Unlike traditional antisense oligonucleotides that target mRNA, Ag-PNAs are designed to bind directly to the genomic DNA sequence of the target gene, inhibiting its transcription (anti-gene mechanism). *MYC* is a well-known proto-oncogene that is frequently overexpressed in a wide range of human cancers, where it drives cell proliferation, metabolic reprogramming, and survival. BGA003 is currently in the preclinical development stage, with research completed and preclinical studies ongoing.
- Other names
- Ag-PNAPNA anti-gene oligonucleotide
02
Targets
MYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on BGA003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGA003.